P I Industries Ltd Q3 FY2024 Concall Summary

Key Takeaways

• 18% revenue growth, exports lead: Exports grew 23% while domestic declined 6% on monsoon deficits and elevated channel inventory; new products commercialized in the last three years drove over 60% of the quarter's growth.
• One-off theft recovery flatters margins: A ₹70 crore insurance recovery added ~300 bps to EBITDA; even without it, favorable product mix and operating leverage supported a sustainable 25%-26% EBITDA margin range.
• Non-AgChem diversification is accelerating: The share of non-AgChem molecules in new enquiries grew 30%, and management targets more than 20%-25% of revenue from pharma and non-AgChem CSM exports within 4-5 years.
• Patent expiry fears are overstated: The key solo-product patent has expired in some countries, but developed-market sales are predominantly combination formulations with significantly longer patent life, muting the genericization impact.
• What to watch next quarter: FY25 guidance, the pace of pharma integration spend and revenue visibility, and whether domestic agchem challenges ease as the rabi season progresses.

Export Engine & New Product Momentum

• Early-stage molecules drive durability: Export growth is anchored in patented molecules still in early stages of their lifecycle, gaining registrations in newer geographies, which management expects to sustain growth for several years.
• New products dominate incremental growth: More than 50% of Q3 growth came from new products, and newly commercialized products contributed over 60% growth in the quarter, confirming the pipeline-to-revenue conversion is working.
• R&D pipeline depth: 50 new molecules are in the R&D pipeline, with 30% of new AgChem molecules having a good runway and slated for future commercialization.
• Client relationships deepening: Management pushed back on China-resourcing fears, stating that because PI focuses on early-stage molecules, customers evaluating China as an alternative is not a relevant headwind; engagements have only deepened with strategic partners.
• Capacity keeps pace: 10%-15% annual throughput improvement from existing facilities, plus work on flow chemistry technologies, supports volume growth without step-change capex.

Singhal: "Over the years, we have supported the growth of advanced molecules of innovators and given the pipeline we have built, this cycle is continuous. It is a kind of natural virtuous cycle replenishing itself with the pipeline of products and new engagements."

Domestic AgChem: Near-Term Pain, Portfolio Remedy

• External headwinds persist: Domestic revenue fell 6% as a monsoon deficit in the south depleted reservoir levels and elevated row-crop inventory weighed on offtake; management expects these challenges to continue in Q4.
• Margin discipline over volume chase: PI chose not to chase volumes by liberalizing credit norms or cutting price, which protected domestic margins despite the top-line decline.
• New launches provide offsets: Five new products launched this fiscal year, including CLARET (paddy insecticide), EKETSU (patented rice herbicide), and KADETT (soyabean/groundnut fungicide), with new products performing well in chili, seasonal vegetables, and wheat.
• Registration pipeline building: Over 20 products are under registration and development for the domestic market, intended to drive growth in coming years.
• Horticulture and biologicals emerging: The Jivagro platform carries 60 brands targeting horticulture, while the biological portfolio of 8 products, including the bio-fungicide PIILIN and bio-nutrient AMINOGROW, is growing strongly.

Pharma & Non-AgChem Diversification

• CRDMO platform taking shape: PI Health Sciences is integrating acquired CRO, CDMO, and API assets into a single CRDMO platform, with investments flowing into R&D, manufacturing sites in India and Europe, and new systems and processes.
• Development spend running elevated: Resources are being augmented across R&D, business development, and managerial functions during the integration; this spend may continue for another quarter or two as optimization proceeds.
• Long-term margin parity expected: Once the development phase of a couple of years concludes, pharma EBITDA margins and financial parameters are expected to align with PI's core business today.
• Non-AgChem enquiry mix shifting: The share of non-AgChem molecules in new enquiries has grown 30%, spanning electronic chemicals and other specialty chemicals, signaling broadening demand beyond the agchem core.
• Revenue visibility still building: Management expects much better visibility on pharma revenue scale-up and margin profile in FY25 and FY26 over the next few quarters, but declined to quantify current pharma client numbers citing confidentiality agreements.

Sarna: "Our objective is over the next 4-5 years, more than 20%-25% of our Company's revenue should be from non-AgChem areas including pharma as well as our portfolio of non-AgChem in our CSM exports. We are progressing well in that direction."

Patent Expiry & Competitive Dynamics

• Combination-formulation buffer: The solo-product patent has already expired in a few countries and will expire in other major countries in the next few years, but in most developed markets the ultimate products sold are combination formulations with significantly longer patent life, so the genericization impact will be less significant than feared.
• Pricing erosion data is second-hand: Management cited market intelligence of 10%-15% pricing erosion in markets where the product became generic (Australia, Argentina) but stated it does not have first-hand information since registrations are handled by the innovator, not PI.
• No worst-case precedent offered: When asked for historical worst-case pricing cuts on patented products turning generic, management deflected, calling it a standard price-volume curve with nothing definable as worst or best case.

Sarna: "The solo product patent has already expired in a few countries, and in other major countries, it will expire in the next few years. But the important point to understand here is that in most of the developed markets/countries, the ultimate products sold are the combination-formulations products having a significantly longer patent life than the next few years."

Margins, Cash Flow & One-Offs

• Theft recovery flatters the quarter: A ₹70 crore insurance recovery from previously written-off inventory added ~300 bps to EBITDA; the underlying margin improvement came from favorable product mix and operating leverage, not volume.
• Sustainable band set at 25%-26%: Management considers this a sustainable EBITDA margin level going forward, though it remains sensitive to product mix and development spending in pharma, agchem, and biologicals.
• Cash conversion improving: Cash flow from operations rose 16% on higher EBITDA and disciplined working capital; trade working capital days reduced by 10 to 80 days, and inventory days fell to ~59 days.
• Tax rate to stay low: The effective tax rate for the year is 11.56%, benefiting from export revenue growth; management expects 14%-15% to continue for at least one more year.
• Red Sea costs largely pass through: Some shipments to Europe and the US faced higher costs, but in most cases these will be passed on to customers per general commercial understanding.

Capex & Inorganic Appetite

• Annual organic capex normalizing at ₹600-800 crore: Management anticipates close to ₹800 crore of annual capex going forward, with more clarity by Q4 end; this covers both capacity throughput improvements and new capability build-out.
• Inorganic opportunities actively evaluated: PI is seeking and evaluating new inorganic opportunities to complement organic growth, though no specific targets were disclosed.
• Pharma integration spend still optimizing: Development spending in pharma may continue for a quarter or two as the company completes integration of acquired assets and sets up new systems; clear visibility on the scale-up trajectory is expected over the next few quarters.

Guidance & Commitments

Key Metrics